PharmaTher Entered into a Development Agreement with CCBIO to Develop and Commercialize Wearable Ketamine Delivery Device
Shots:
- The collaboration will combine PharmaTher’s ketamine formulation with CCBIO’s Felice Dose wearable delivery device to develop wearable ketamine delivery solutions for mental health, neurological & pain disorders. The collaboration complements PharmaTher’s portfolio including injectable, IV & microneedle patch
- PharmaTher's device aims to convert IV & IM ketamine delivery to SC which can improve safety & efficacy, reduce side effects, improve patient comfort & adherence, reduce time burden & expands the use of ketamine
- CCBIO will lead development, clinical manufacturing activities & support PharmaTher’s regulatory submissions. The clinical studies are expected to be initiated in Q1’23 for the wearable ketamine delivery device
Ref: Globenewswire | Image: PharmaTher
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
